Biogen (BIIB) Revenue — Quarter Ended Jun 30, 2023
Revenue for the reporting quarter declined slightly compared to the immediately preceding quarter and more notably compared to the same quarter one year earlier. The filing context discusses recent regulatory developments for a key product.
Key takeaway
Quarter ended Jun 30, 2023 · FY2023 Q2
Revenue for the reporting quarter declined slightly compared to the immediately preceding quarter and more notably compared to the same quarter one year earlier. The filing context discusses recent regulatory developments for a key product.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.5B
Revenue reported for this quarter.
Quarter-over-quarter
-0.3%
Change from the immediately preceding quarter.
Year-over-year
-5.1%
Change from the comparable year-ago quarter.
Trailing four quarters
$10B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2022 | $2.5B | -9.7% |
| Dec 31, 2022 | $2.5B | -6.9% |
| Mar 31, 2023 | $2.5B | -4.9% |
| Jun 30, 2023 | $2.5B | -5.1% |
Revenue performance
Revenue decreased from the prior quarter, continuing a trend of sequential declines. The year-over-year comparison also showed a decrease.
Quarterly comparison
Compared to the previous quarter, revenue was slightly lower. Relative to the same quarter a year ago, the decline was more pronounced.
What to watch
The filing context notes recent regulatory approvals that could influence future revenue trends.